Regulation of bim in glucocorticoid-mediated osteoblast apoptosis

✍ Scribed by B. Espina; M. Liang; R.G.G. Russell; P.A. Hulley

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 335 KB
• Volume: 215
• Category: Article
• ISSN: 0021-9541
• DOI: 10.1002/jcp.21335

✦ Synopsis

Abstract

Osteoblasts undergo apoptosis both in vitro and in vivo in response to high dose glucocorticoid (GC) treatment. However, the molecular mechanisms remain elusive, hindering the prevention and treatment of this side‐effect. Apoptosis was induced by dexamethasone (Dex) in murine MBA‐15.4 osteoblasts within 24–48 h of treatment. We found dose‐ and time‐dependent upregulation of Bim protein, a pro‐apoptotic Bcl‐2 family member, with highest levels at 24–48 h for 1 µM Dex. This was also observed in primary human bone marrow stromal cells. Bim is subjected to stringent transcriptional and post‐translational regulation in osteoblasts. Bim mRNA was upregulated in response to 1 µM Dex; both cycloheximide and the GC receptor antagonist, RU486, prevented Dex‐induction of Bim protein, indicating transcriptional regulation involving the GC receptor. The proteasome inhibitor, MG132, potently increased Bim protein levels. Bim was also upregulated in osteoblasts undergoing apoptosis in response to serum deprivation and matrix detachment. Gene silencing experiments show that short interference RNA (siRNA) specific for Bim or the downstream effector Bax both reduced apoptosis induced by Dex in osteoblastic cells. These findings suggest that Bim is a novel regulator of osteoblast apoptosis and may be a therapeutic target. J. Cell. Physiol. 215: 488–496, 2008. © 2007 Wiley‐Liss, Inc.